Eli Lilly Takes Legal Action Against Companies for Unapproved Weight Loss Drugs Distribution

Eli Lilly and Co. has initiated a series of legal actions targeting companies allegedly selling unapproved compounded tirzepatide products, marketed for weight loss, under the brands Zepbound and Mounjaro. The lawsuits are filed in federal courts in both New Jersey and California, accusing Willow Health Services and three additional entities of distributing these products without the necessary approval or adequate testing by the U.S. Food and Drug Administration (FDA). This legal maneuver is viewed by some as an effort by major pharmaceutical firms to tighten market control, potentially curbing patient choices in the process. For more detailed insights into these legal proceedings, click here.